Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly
If patients have a severe obesity-related complication including but not limited to hypertension, type 2 diabetes, CVD, dyslipidemia and a BMI of 27 mg/kg 2 or greater, then concurrent initiation of weight-loss medication with lifestyle interventions can be considered, according to the guideline
405 A prospective, randomized, blinded study compared the effects of topiroxostat with allopurinol and suggested that topiroxostat may lead to a reduction in left ventricular end-diastolic pressure, indicating a potential benefit for cardiac function
New and existing patients are eligible
Compounding is actually the original form of pharmacy practice
It helps white blood cells (like T-cells and natural killer cells) work more effectively to fight off infections and maintain balance in the immune response